Developmental funds provide an essential base of support for the strategic initiatives of the Vanderbiltlngram Cancer Center (VICC) consistent with its overall planning processes. During the current project period, this support was applied in three areas: 1) recruitment of new faculty, 2) support of pilot projects and 3) the development of a new shared resource. A total of nine new faculty members were provided with recruitment support;a significant number of them have obtained peer-reviewed funding. A total of 27 pilot projects were funded over the project period with a significant publication and subsequent funding record. Finally, developmental funds supported the Survey and Biospecimen Shared Resource, now being presented as an established shared resource in this application. Given the continued growth in the VICC overall research enterprise and the successful use of developmental funds in the current project period, a new request of $725,000 per year is felt to be justified. This would be allocated as $450,000 per year for new faculty recruitment in targeted strategic areas, including but not limited to cancer genetics, genomics and epigenetics, cancer drug discovery, personalized cancer medicine. Phase I investigations, cancer epidemiology and population-based research, cancer control and hematologic and neurologic malignancies. A request of $275,000 per year will support three types of pilot projects: 1) highly innovative projects focusing on proof-of-concept or translational research, 2) preliminary collaborative investigations leading to multi-investigator grants, and 3) projects that closely align to our strategic plan in order to enhance key initiatives. The VICC has a proven track record in the stewardship of these funds. The current request, in concert with the continued commitment of VICC discretionary funds, enables the Director to support activities critical to the sustained research excellence of the VICC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA068485-17
Application #
8545003
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
17
Fiscal Year
2013
Total Cost
$560,871
Indirect Cost
$86,081
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Payton, Rebecca R; Rispoli, Louisa A; Nagle, Kimberly A et al. (2018) Mitochondrial-related consequences of heat stress exposure during bovine oocyte maturation persist in early embryo development. J Reprod Dev 64:243-251
Kovtun, Oleg; Tomlinson, Ian D; Bailey, Danielle M et al. (2018) Single Quantum Dot Tracking Illuminates Neuroscience at the Nanoscale. Chem Phys Lett 706:741-752
Goff, Laura W; Azad, Nilofer S; Stein, Stacey et al. (2018) Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer. Invest New Drugs :
Weigl, Korbinian; Thomsen, Hauke; Balavarca, Yesilda et al. (2018) Genetic Risk Score Is Associated With Prevalence of Advanced Neoplasms in a Colorectal Cancer Screening Population. Gastroenterology 155:88-98.e10
Johnson, Douglas B; Dahlman, Kimberly B (2018) Class Matters: Sensitivity of BRAF-Mutant Melanoma to MAPK Inhibition. Clin Cancer Res 24:6107-6109
Schlegel, Cameron; Lapierre, Lynne A; Weis, Victoria G et al. (2018) Reversible deficits in apical transporter trafficking associated with deficiency in diacylglycerol acyltransferase. Traffic 19:879-892
Hebron, Katie E; Li, Elizabeth Y; Arnold Egloff, Shanna A et al. (2018) Alternative splicing of ALCAM enables tunable regulation of cell-cell adhesion through differential proteolysis. Sci Rep 8:3208
Bangaru, Sandhya; Zhang, Heng; Gilchuk, Iuliia M et al. (2018) A multifunctional human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HA. Nat Commun 9:2669
Gilchuk, Pavlo; Kuzmina, Natalia; Ilinykh, Philipp A et al. (2018) Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein. Immunity 49:363-374.e10
Du, Zhenfang; Lovly, Christine M (2018) Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer 17:58

Showing the most recent 10 out of 2462 publications